advertisement
Williams PA 132
Showing records 1 to 25 | Display only abstracts from Williams PA in IGR 22-1107563 NAD salvage pathway machinery expression in normal and glaucomatous retina and optic nerve
Tribble JR; Hagström A; Jusseaume K; Lardner E; Lardner E; Wong RC; Stålhammar G; Williams PA
Acta neuropathologica communications 2023; 11: 18 (IGR: 23-4)
104984 Widespread retina and optic nerve neuroinflammation in enucleated eyes from glaucoma patients
Rutigliani C; Tribble JR; Hagström A; Lardner E; Lardner E; Jóhannesson G; Stålhammar G; Williams PA
Acta neuropathologica communications 2022; 10: 118 (IGR: 23-2)
100763 Valproic Acid Reduces Neuroinflammation to Provide Retinal Ganglion Cell Neuroprotection in the Retina Axotomy Model
Tribble JR; Kastanaki E; Uslular AB; Rutigliani C; Enz TJ; Williams PA
Frontiers in cell and developmental biology 2022; 10: 903436 (IGR: 23-1)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Mouhammad ZA
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Enz TJ; Bittner M
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Vohra R
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Tribble JR
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Horwitz A; Thein AS
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Williams PA
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Rovelt J
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Thiel MA; Schmid MK
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Cvenkel B
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Bachmann LM
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Williams PA
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
98712 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
Bochmann F
Translational vision science & technology 2022; 11: 1 (IGR: 22-4)
99062 Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?
Azuara-Blanco A; Kolko M
Frontiers in neuroscience 2022; 16: 824054 (IGR: 22-4)
96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
De Moraes CG
JAMA ophthalmology 2022; 140: 11-18 (IGR: 22-3)
96065 Comparison of Glaucoma-Relevant Transcriptomic Datasets Identifies Novel Drug Targets for Retinal Ganglion Cell Neuroprotection
Enz TJ; Tribble JR
Journal of clinical medicine 2021; 10: (IGR: 22-3)
96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
John SWM; Williams PA
JAMA ophthalmology 2022; 140: 11-18 (IGR: 22-3)
96065 Comparison of Glaucoma-Relevant Transcriptomic Datasets Identifies Novel Drug Targets for Retinal Ganglion Cell Neuroprotection
Williams PA
Journal of clinical medicine 2021; 10: (IGR: 22-3)
96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
Blumberg DM; Cioffi GA; Liebmann JM
JAMA ophthalmology 2022; 140: 11-18 (IGR: 22-3)
94852 Neuroprotection in Glaucoma: NAD/NADH Redox State as a Potential Biomarker and Therapeutic Target
Petriti B; Williams PA; Lascaratos G; Chau KY; Garway-Heath DF
Cells 2021; 10: (IGR: 22-2)
92681 Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction
Tribble JR; Otmani A; Otmani A; Sun S; Ellis SA; Cimaglia G; Vohra R; Jöe M; Lardner E; Lardner E; Venkataraman AP; Domínguez-Vicent A; Kokkali E; Kokkali E; Rho S; Jóhannesson G; Burgess RW; Fuerst PG; Brautaset R; Kolko M; Morgan JE; Crowston JG; Votruba M; Williams PA
Redox biology 2021; 43: 101988 (IGR: 22-1)
90934 Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin
Harder JM
Proceedings of the National Academy of Sciences of the United States of America 2020; 117: 33619-33627 (IGR: 21-4)
91347 Retinal Ganglion Cell Degeneration in a Rat Magnetic Bead Model of Ocular Hypertensive Glaucoma
Tribble JR
Translational vision science & technology 2021; 10: 21 (IGR: 21-4)